EGFR and non-small cell lung carcinoma: In the context of EGFR-mutant non-small cell lung cancer (NSCLC), TP53 loss-of-function mutations have been implicated in early resistance to the EGFR tyrosine kinase inhibitor (TKI) osimertinib (18).